Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Body fatness, body core temperature, and heat loss during moderate-intensity exercise.

Limbaugh JD, Wimer GS, Long LH, Baird WH.

Aviat Space Environ Med. 2013 Nov;84(11):1153-8.

PMID:
24279228
2.

VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells.

Currier MA, Eshun FK, Sholl A, Chernoguz A, Crawford K, Divanovic S, Boon L, Goins WF, Frischer JS, Collins MH, Leddon JL, Baird WH, Haseley A, Streby KA, Wang PY, Hendrickson BW, Brekken RA, Kaur B, Hildeman D, Cripe TP.

Mol Ther. 2013 May;21(5):1014-23. doi: 10.1038/mt.2013.39. Epub 2013 Mar 12.

3.

VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy.

Eshun FK, Currier MA, Gillespie RA, Fitzpatrick JL, Baird WH, Cripe TP.

Gene Ther. 2010 Jul;17(7):922-9. doi: 10.1038/gt.2010.82. Epub 2010 May 27.

4.

Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus.

Mahller YY, Williams JP, Baird WH, Mitton B, Grossheim J, Saeki Y, Cancelas JA, Ratner N, Cripe TP.

PLoS One. 2009;4(1):e4235. doi: 10.1371/journal.pone.0004235. Epub 2009 Jan 21.

5.

Molecular analysis of human cancer cells infected by an oncolytic HSV-1 reveals multiple upregulated cellular genes and a role for SOCS1 in virus replication.

Mahller YY, Sakthivel B, Baird WH, Aronow BJ, Hsu YH, Cripe TP, Mehrian-Shai R.

Cancer Gene Ther. 2008 Nov;15(11):733-41. doi: 10.1038/cgt.2008.40. Epub 2008 Jun 13.

6.

Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors.

Mahller YY, Vaikunth SS, Ripberger MC, Baird WH, Saeki Y, Cancelas JA, Crombleholme TM, Cripe TP.

Cancer Res. 2008 Feb 15;68(4):1170-9. doi: 10.1158/0008-5472.CAN-07-2734.

Supplemental Content

Loading ...
Support Center